NanoString Technologies Inc (NSTG) : Hamilton Lane Advisors added new position in NanoString Technologies Inc during the most recent quarter end. The investment management firm now holds 181,370 shares of NanoString Technologies Inc which is valued at $2,887,410 , the company said in a statement filed on Apr 13, 2016 with the SEC.NanoString Technologies Inc makes up approximately 1.36% of Hamilton Lane Advisors’s portfolio.
NanoString Technologies Inc opened for trading at $15.79 and hit $16.21 on the upside on Monday, eventually ending the session at $16.09, with a gain of 1.07% or 0.17 points. The heightened volatility saw the trading volume jump to 1,02,856 shares. Company has a market cap of $316 M.
Other Hedge Funds, Including , Creative Planning reduced its stake in NSTG by selling 761 shares or 29.69% in the most recent quarter. The Hedge Fund company now holds 1,802 shares of NSTG which is valued at $28,021.
On the company’s financial health, NanoString Technologies Inc reported $-0.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Feb 29, 2016. Analyst had a consensus of $-0.47. The company had revenue of $22.30 million for the quarter, compared to analysts expectations of $21.12 million. The company’s revenue was up 42.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.68 EPS.
NanoString Technologies Inc. is engaged in detection identification and quantification of individual target molecules in a biological sample by attaching a color coded fluorescent reporter to each target molecule of interest. The Company markets its nCounter Analysis System consisting of instruments and consumables including its Prosigna Breast Cancer Assay to academic government and biopharmaceutical and clinical laboratory customers. The Company’s nCounter Analysis System is an automated multi-application digital detection and counting system which directly profiles molecules using a barcoding technology. As of December 31 2014 the Company has an installed base of 264 systems. Prosigna the Company’s molecular diagnostic test is based on a collection of 50 genes known as the PAM50 gene signature.